Munguva pfupi yapfuura, Merck & Co., Inc. (Merck) yakazivisa kuti mushonga wayo wePD-1 inhibitor, pembrolizumab, wabvumidzwa neNational Medical Products Administration (NMPA) yeChina kuti ushandiswe pamwe chete nelenvatinib uye transarterial chemoembolization (TACE) pakurapa varwere vane carcinoma yehepatocellular isingabvisike, isingaparare.
Kubvumidzwa kwechiratidzo chitsva ichi kwakavakirwa padata kubva muongororo yekiriniki yePhase III LEAP-012. Muchidzidzo ichi chePhase III chenzvimbo dzakawanda, chisina kurongeka, chisina kupofumadzwa kaviri, (LEAP-012), varwere mazana mana nemakumi masere vakanyoreswa uye vakagoverwa zvisina kurongeka kuti vagamuchire lenvatinib pamwe neTACE pamwe nepembrolizumab (n=237) kana TACE pamwe nedual placebo (n=243).
Zvakabuda zvakaratidza kuti mwero wepakati wekurarama usina progression-free survival (PFS) waiva mwedzi 14.6 muboka relenvatinib pamwe neTACE pamwe nepembrolizumab, zvichienzaniswa nemwedzi 10.0 muboka replacebo. Mwero wekurarama kwese kwemwedzi 24 (OS) waiva 75% uye 69%, zvichiteerana.
Lenvatinibmushonga unodzivirira kinase unoshandiswa kurapa mamwe marudzi egomarara. Zvinodzivirira kinase imishonga inodzivirira enzyme inovhara kushanda kweprotein kinase imwe kana kupfuura.
Pembrolizumab iantibody yeIgG4 kappa yakagadzirwa nemunhu inonangwa kurwisa PD-1 (programmed death receptor-1) pamusoro pemalymphocytes. Iyo PD-1 receptor inopa "nzvimbo yekutarisa immune system," iyo inobatsira kudzivirira immune system kuti isazvirwise. Mamwe marudzi emamota ane PD-L1 yakawanda (programmed death receptor ligand-1). Mamwe marudzi emamota anoshandisa adaptive immune resistance kwaanoshandisa natural physiology yePD-L1 induction (kudzivirira kukuvara kunokonzerwa neimmune kubva kuhutachiona) uye kuigadzirisa kune anti-bumor responses. Kana PD-L1 ikasangana nePD-1, basa reT-cell rinodzikira; pembrolizumab inovhara PD-1: PDL-1 complex formation ichibvumira kuvandudzwa kweT-cell mediated kill.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Chikumi-19-2025